Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 18, 2023 - Issue
Submit an article Journal homepage
317
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States

Michael Bogart1 U.S. Value Evidence and Outcomes, R&D US, GSK, Research Triangle Park, NC, USAView further author information
,
Guillaume Germain2 Groupe d’analyse, Ltée, Montréal, QC, CanadaView further author information
,
François Laliberté2 Groupe d’analyse, Ltée, Montréal, QC, CanadaView further author information
,
Dominique Lejeune2 Groupe d’analyse, Ltée, Montréal, QC, CanadaView further author information
&
Mei Sheng Duh3 Analysis Group, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5035-6687View further author information
ORCID Icon
Pages 1575-1586 | Received 11 Jan 2023, Accepted 03 Jul 2023, Published online: 24 Jul 2023

References

  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease – 2022 report; 2022. Available from: https://goldcopd.org/2022-gold-reports/. Accessed April 15, 2022.
  • Hindelang M, Kirsch F, Leidl R. Effectiveness of non-pharmacological COPD management on health-related quality of life - a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2020;20(1):79–91.
  • World Health Organization. Chronic obstructive pulmonary disease (COPD); 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)). Accessed April 15, 2022.
  • GlaxoSmithKline. Prescribing information for Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder); 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209482s003lbl.pdf. Accessed April 15, 2022.
  • AstraZeneca. Prescribing information for Breztri Aerosphere™ (budesonide, glycopyrrolate, and formoterol fumarate inhalation aerosol); 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212122s000lbl.pdf. Accessed April 15, 2022.
  • Bogart M, Stanford RH, Laliberte F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352.
  • Bourbeau J, Bafadhel M, Barnes NC, et al. Benefit/risk profile of single-inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:499–517.
  • Miravitlles M, Marin A, Huerta A, Carcedo D, Villacampa A, Puig-Junoy J. Estimation of the clinical and economic impact of an improvement in adherence based on the use of once-daily single-inhaler triple therapy in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1643–1654.
  • Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446.
  • Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
  • Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.
  • Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.
  • Diette GB, Dalal AA, D’Souza AO, Lunacsek OE, Nagar SP. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. Int J Chron Obstruct Pulmon Dis. 2015;10:415–422.
  • Schabert V, Shah S, Holmgren U, Cabrera C. Prescribing pathways to triple therapy in patients with chronic obstructive pulmonary disease in the United States. Ther Adv Respir Dis. 2021;15:17534666211001018.
  • Lassan S, Keszegh J, Lassanova M. Characteristics of COPD patients treated with single-inhaler triple therapy in real-life clinical practice. Bratisl Lek Listy. 2022;123(1):27–36.
  • Sansbury LB, Bains C, Lipson DA, Ismaila AS, Landis SH. Real-world treatment patterns of multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in UK general practice. Int J Chron Obstruct Pulmon Dis. 2021;16:1255–1264.
  • Lane DC, Stemkowski S, Stanford RH, Tao Z. Initiation of triple therapy with multiple inhalers in chronic obstructive pulmonary disease: an analysis of treatment patterns from a U.S. retrospective database study. J Manag Care Spec Pharm. 2018;24(11):1165–1172.
  • Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study. Respir Med. 2018;142:73–80.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.